SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Seneca Biopharma, Inc. Announces Completion Of Phase II Clinical Study In China For The Treatment Of Ischemic Stroke

GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ --Seneca Biopharma, Inc. (NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced

· 09/10/2020 08:12

GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ --Seneca Biopharma, Inc. (NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the last subject completed their final follow-up assessment in the Company's non-GCP Phase II study in Beijing, China evaluating NSI-566 for the treatment of chronic ischemic stroke. With this milestone achieved, the company remains on schedule to release top line data for the study during the fourth quarter of 2020.